ArticleCell death & disease2024
Targeting LINC00152 activates cAMP/Ca
Abstract read
In one paragraph
Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC.Cell reports. Medicine · 2026Article
- Multi-scale transcriptomic integration reveals LINC00152-high tumor cells promote TGCT progression and T cell exhaustion.British journal of cancer · 2026Article
- SERPINE2-mediated activation of JAK2/STAT3 facilitates NRF2 nuclear translocation and GCLC transcription to confer ferroptosis resistance and lenvatinib resistance in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Targeting ZNF570 activates ferroptosis to reverse tamoxifen resistance in ER + breast cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ferroptosis as a therapeutic target in cancer: mechanisms, immune interactions, and emerging strategies.Molecular cancer · 2026Review
- The Intricate Interplay of Noncoding RNAs and the Gut Microbiome in Gastrointestinal and Endocrine-Related Cancers.Sub-cellular biochemistry · 2026Review
- Epigenetic modifications in ferroptosis regulation of breast cancer.American journal of cancer research · 2026Review
- Targeting Ferroptosis to Overcome Drug Resistance in Cancer: Molecular Mechanisms and Therapeutic Prospects.Biomolecules & therapeutics · 2026Review
- The impact of epigenetics on tumor metabolism: Friend or foe in drug response?Frontiers in epigenetics and epigenomics · 2026Review
- Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors.Cancers · 2025Review
- The role of UPR-related long noncoding RNAs in development of endocrine resistance in breast cancer.International journal of cancer · 2025Review
- Targeting the redox-programmed cell death axis in breast cancer: from molecular mechanisms to therapeutic resistance.Cell death discovery · 2025Review
- Dual action of pyrimidine derivatives: Targeting tamoxifen resistance in breast cancer.Translational oncology · 2025Article
- Ferroptosis-related LncRNAs in diseases.BMC biology · 2025Review
- HSPBiomedicines · 2025Article
- Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2- Breast Cancer.International journal of molecular sciences · 2025Review
- Ultrasound Imaging and Guidance for Tamoxifen-Associated Achilles Tendinopathy.European journal of breast health · 2025Article
- Nanomaterial-Driven Regulated Cell Death: Mechanistic Insights and Novel Strategies for Tumor Therapy.International journal of nanomedicine · 2025Review
- The multifaceted perspectives on the regulation of lncRNAs in hepatocellular carcinoma ferroptosis: from bench-to-bedside.Clinical and experimental medicine · 2024Review
- Review
Corrections and comments
- Update of
Authors and funding
22 authors.
Ozge SaatciDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID 0000-0002-0124-044X
Rashedul AlamDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Kim-Tuyen Huynh-DamDepartment of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, SC, 29208, USA.
Aynur IsikDepartment of Pathology, Faculty of Medicine, Hacettepe University, 06100, Ankara, Turkey.
Meral UnerDepartment of Pathology, Faculty of Medicine, Hacettepe University, 06100, Ankara, Turkey.ORCID 0000-0001-9927-1246
Nevin BelderDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey.ORCID 0000-0001-9353-9387
Pelin Gulizar ErsanDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey.ORCID 0000-0003-3637-4090
Unal Metin TokatDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey.ORCID 0000-0003-0026-368X
Burge UlukanDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID 0000-0002-1101-8834
Metin CetinDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Kubra CalisirDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID 0000-0002-6204-1022
Mustafa Emre GedikDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Hilal BalDepartment of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey.ORCID 0000-0003-1668-6070
Ozlem Sener SahinDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
Yasser RiazalhosseiniDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada.
Denis ThieffryDépartement de biologie de l'Ecole normale supérieure, PSL Université, 75005, Paris, France.
Daniel GautheretInstitute for Integrative Biology of the Cell (I2BC), Université Paris-Saclay, CNRS, CEA, 91190, Gif-sur-Yvette, France.
Besim OgretmenDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.ORCID 0000-0002-1019-5660
Sercan AksoyDepartment of Medical Oncology, Hacettepe University Cancer Institute, 06100, Ankara, Turkey.ORCID 0000-0003-4984-1049
Aysegul UnerDepartment of Pathology, Faculty of Medicine, Hacettepe University, 06100, Ankara, Turkey.
Aytekin AkyolDepartment of Pathology, Faculty of Medicine, Hacettepe University, 06100, Ankara, Turkey.
Ozgur SahinDepartment of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA. sahin@musc.edu.ORCID 0000-0002-8033-7089
Funding
RESEARCH PILOT PROJECTS PROGRAMP30GM103339 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HANNUN, YUSUF AWNI · 2012 to 2016
$5.4MMUSC FACIL EXPANSION &RENOV: SLE C06RR015455 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND, JOHN R · 2002 to 2002
$2.0MOvercoming chemoresistance in triple negative breast cancerR01CA267101 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Ozgur Sahin · 2022 to 2026
$1.8MInhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplificationR01CA251374 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI SAHIN, OZGUR · 2021 to 2025
$1.7MAmerican Cancer Society (American Cancer Society, Inc.) RSG-19-194-01-CSMFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01CA251374Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01CA267101NCI NIH HHS R01 CA251374NCI NIH HHS R01 CA267101NCRR NIH HHS C06 RR015455NIGMS NIH HHS P30 GM103339Susan G. Komen (Susan G. Komen Breast Cancer Foundation) GTDR17500160
Abstract
Tamoxifen has been the mainstay therapy to treat early, locally advanced, and metastatic estrogen receptor-positive (ER + ) breast cancer, constituting around 75% of all cases. However, the emergence of resistance is common, necessitating the identification of novel therapeutic targets. Here, we demonstrated that long-noncoding RNA LINC00152 confers tamoxifen resistance by blocking tamoxifen-induced ferroptosis, an iron-mediated cell death. Mechanistically, inhibiting LINC00152 reduces the mRNA stability of phosphodiesterase 4D (PDE4D), leading to activation of the cAMP/PKA/CREB axis and increased expression of the TRPC1 Ca
Indexed as
Breast NeoplasmsCalciumCyclic AMPDrug Resistance, NeoplasmFerroptosisRNA, Long NoncodingTamoxifenAnimalsCell Line, TumorFemaleHumansMCF-7 CellsMiceReactive Oxygen SpeciesReceptors, EstrogenCalciumCyclic AMPReactive Oxygen SpeciesReceptors, EstrogenRNA, Long NoncodingTamoxifen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.